Why Do Patients with Advanced Lymphoma Experience Headaches?

Lymphoma, particularly in its advanced stages, can cause headaches through several distinct pathological mechanisms. While lymphoma itself is a malignancy of lymphoid tissue—most commonly originating in lymph nodes, bone marrow, or extranodal sites—headache is not a typical early symptom. However, in late-stage disease, headache may emerge as a red flag indicating central nervous system (CNS) involvement.

One primary cause is leptomeningeal lymphomatosis—the infiltration of malignant lymphocytes into the leptomeninges (the pia mater and arachnoid mater). This disrupts cerebrospinal fluid (CSF) dynamics, increases intracranial pressure, and triggers meningeal irritation, resulting in persistent, often worsening headaches—frequently accompanied by nausea, photophobia, neck stiffness, or altered mental status.

Secondary causes include cerebral parenchymal involvement, where lymphomatous masses form within brain tissue (primary CNS lymphoma or systemic lymphoma with brain metastases), leading to mass effect, edema, or increased intracranial pressure. Additionally, paraneoplastic syndromes—immune-mediated neurological complications—can rarely manifest as headache, though this is less common than direct infiltration.

Other contributing factors in advanced disease include metabolic derangements (e.g., hypercalcemia, hyponatremia), treatment-related neurotoxicity (e.g., high-dose methotrexate or corticosteroid withdrawal), or opportunistic CNS infections due to profound immunosuppression. Importantly, new-onset or progressively worsening headache in a patient with known lymphoma warrants urgent neuroimaging (contrast-enhanced MRI of the brain and spine) and CSF analysis—including flow cytometry and molecular studies—to evaluate for CNS relapse or progression.

Clinicians must distinguish lymphoma-associated headache from more common benign causes—but in the context of advanced disease, it should never be dismissed as nonspecific. Early recognition and intervention are critical, as CNS involvement significantly impacts prognosis and necessitates tailored therapeutic strategies, including intrathecal chemotherapy, high-dose systemic agents with CNS penetration, or radiation therapy.